NASDAQ: APRE
Aprea Therapeutics, Inc.
Healthcare · Biotechnology
After hours: $0.65(+0.57%) · as of 7:34 PM ET
Market Cap
$4.22M
52w High
$1.79
52w Low
$0.55
P/E
-0.37
Volume
37.96K
Outstanding Shares
6.49M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 60.59% over the last year. Revenue declined 90.8% over the trailing twelve months. Operating margin moved from -1,187.69% to -10,649.87%. Free cash flow grew 7.86% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/S, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at -10,649.87%. Revenue declined 90.8% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments.
Valuation
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
4
Buy
2
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 11, 2026
Q3 FY26 · EPS est -$0.18 · Revenue est $253K
View